RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
China Grand Enterprises, an investment firm, together with its affiliate Huadong Medicine are in early stage talks to acquire Sinclair Pharma, a UK aesthetics company. Sinclair climbed 23.5% on the news, raising its market capitalization to $156 million. Based on its collagen stimulation technology, Sinclair offers a variety of minimally invasive, long-duration fillers and smoothers for the skin. Under British rules, China Grand has 30 days to strike a final deal for Sinclair.
Source: China Biotoday
